Urogen Pharma Ltd
URGN23.760USD
+0.360+1.54%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
1.11BMarket Cap
LossP/E TTM
More Details of Urogen Pharma Ltd Company
UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).
Urogen Pharma Ltd Info
Ticker SymbolURGN
Company nameUrogen Pharma Ltd
IPO dateMay 04, 2017
CEOBarrett (Elizabeth A)
Number of employees235
Security typeOrdinary Share
Fiscal year-endMay 04
Address9 Ha'ta'asiya St
CityRA'ANANA
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryIsrael
Postal code4365007
Phone97297707601
Websitehttps://www.urogen.com/
Ticker SymbolURGN
IPO dateMay 04, 2017
CEOBarrett (Elizabeth A)
Company Executives of Urogen Pharma Ltd
Name
Name/Position
Position
Shareholding
Change
Dr. Arie S. Belldegrun, M.D.
Dr. Arie S. Belldegrun, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
408.69K
--
Ms. Elizabeth A. (Liz) Barrett
Ms. Elizabeth A. (Liz) Barrett
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
326.69K
--
Mr. Jason Drew Smith
Mr. Jason Drew Smith
Chief Compliance Officer, General Counsel, Corporate Secretary
Chief Compliance Officer, General Counsel, Corporate Secretary
43.30K
+4.37%
Mr. Christopher (Chris) Degnan
Mr. Christopher (Chris) Degnan
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
2.28K
--
Ms. Cynthia M. Butitta
Ms. Cynthia M. Butitta
Independent Director
Independent Director
2.00K
--
Mr. James A. Robinson, Jr.
Mr. James A. Robinson, Jr.
Independent Director
Independent Director
--
--
Dr. Mark P. Schoenberg, M.D.
Dr. Mark P. Schoenberg, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Leana S. Wen, M.D.
Dr. Leana S. Wen, M.D.
Independent Director
Independent Director
--
--
Mr. Vincent Perrone
Mr. Vincent Perrone
Investor Relations
Investor Relations
--
--
Mr. Daniel G. Wildman
Mr. Daniel G. Wildman
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Arie S. Belldegrun, M.D.
Dr. Arie S. Belldegrun, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
408.69K
--
Ms. Elizabeth A. (Liz) Barrett
Ms. Elizabeth A. (Liz) Barrett
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
326.69K
--
Mr. Jason Drew Smith
Mr. Jason Drew Smith
Chief Compliance Officer, General Counsel, Corporate Secretary
Chief Compliance Officer, General Counsel, Corporate Secretary
43.30K
+4.37%
Mr. Christopher (Chris) Degnan
Mr. Christopher (Chris) Degnan
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
2.28K
--
Ms. Cynthia M. Butitta
Ms. Cynthia M. Butitta
Independent Director
Independent Director
2.00K
--
Mr. James A. Robinson, Jr.
Mr. James A. Robinson, Jr.
Independent Director
Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
By BusinessUSD
Name
Revenue
Proportion
Jelmyto
24.21M
0.00%
Relevant data have not been disclosed by the company yet.
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Jelmyto
24.21M
0.00%
Shareholding Stats
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
RTW Investments L.P.
9.71%
Paradigm BioCapital Advisors LP
9.01%
TD Securities, Inc.
6.82%
Morgan Stanley & Co. LLC
5.25%
Jefferies LLC
4.70%
Other
64.52%
Shareholders
Shareholders
Proportion
RTW Investments L.P.
9.71%
Paradigm BioCapital Advisors LP
9.01%
TD Securities, Inc.
6.82%
Morgan Stanley & Co. LLC
5.25%
Jefferies LLC
4.70%
Other
64.52%
Shareholder Types
Shareholders
Proportion
Hedge Fund
29.47%
Research Firm
22.98%
Investment Advisor
19.96%
Investment Advisor/Hedge Fund
19.58%
Insurance Company
4.14%
Venture Capital
3.24%
Individual Investor
2.07%
Corporation
1.79%
Private Equity
1.47%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
311
45.66M
97.55%
-6.58M
2025Q2
285
53.00M
114.72%
+5.27M
2025Q1
290
49.25M
108.64%
+1.67M
2024Q4
280
43.94M
103.24%
-1.94M
2024Q3
262
44.13M
104.63%
-2.19M
2024Q2
247
46.02M
111.40%
+11.07M
2024Q1
255
34.96M
99.86%
+5.57M
2023Q4
237
29.16M
94.80%
+4.33M
2023Q3
238
25.93M
86.41%
+2.69M
2023Q2
222
19.52M
83.40%
-392.05K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
RTW Investments L.P.
4.54M
9.82%
+709.10K
+18.49%
Jun 30, 2025
Paradigm BioCapital Advisors LP
2.33M
5.04%
+2.33M
--
Aug 05, 2025
TD Securities, Inc.
3.19M
6.9%
+1.44M
+82.40%
Jun 30, 2025
Morgan Stanley & Co. LLC
1.47M
3.19%
+1.27M
+633.13%
Jun 30, 2025
Jefferies LLC
2.20M
4.75%
+1.38M
+169.90%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
2.11M
4.56%
-34.56K
-1.61%
Jun 30, 2025
SilverArc Capital Management, LLC
2.02M
4.37%
+641.32K
+46.43%
Jun 30, 2025
Pontifax Venture Capital
1.49M
3.21%
-1.00
-0.00%
Mar 14, 2024
UBS Asset Management Switzerland AG
1.32M
2.85%
--
--
Jan 31, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
ARK Israel Innovative Technology ETF
2.09%
Tema Oncology ETF
1.92%
ALPS Medical Breakthroughs ETF
0.39%
Hypatia Women CEO ETF
0.28%
ProShares Ultra Nasdaq Biotechnology
0.16%
iShares Micro-Cap ETF
0.15%
Fidelity Enhanced Small Cap ETF
0.11%
Vanguard US Momentum Factor ETF
0.1%
Invesco Nasdaq Biotechnology ETF
0.09%
iShares Biotechnology ETF
0.07%
View more
ARK Israel Innovative Technology ETF
Proportion2.09%
Tema Oncology ETF
Proportion1.92%
ALPS Medical Breakthroughs ETF
Proportion0.39%
Hypatia Women CEO ETF
Proportion0.28%
ProShares Ultra Nasdaq Biotechnology
Proportion0.16%
iShares Micro-Cap ETF
Proportion0.15%
Fidelity Enhanced Small Cap ETF
Proportion0.11%
Vanguard US Momentum Factor ETF
Proportion0.1%
Invesco Nasdaq Biotechnology ETF
Proportion0.09%
iShares Biotechnology ETF
Proportion0.07%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Urogen Pharma Ltd?
The top five shareholders of Urogen Pharma Ltd are:
RTW Investments L.P. holds 4.54M shares, accounting for 9.82% of the total shares.
Paradigm BioCapital Advisors LP holds 2.33M shares, accounting for 5.04% of the total shares.
TD Securities, Inc. holds 3.19M shares, accounting for 6.90% of the total shares.
Morgan Stanley & Co. LLC holds 1.47M shares, accounting for 3.19% of the total shares.
Jefferies LLC holds 2.20M shares, accounting for 4.75% of the total shares.
RTW Investments L.P. holds 4.54M shares, accounting for 9.82% of the total shares.
Paradigm BioCapital Advisors LP holds 2.33M shares, accounting for 5.04% of the total shares.
TD Securities, Inc. holds 3.19M shares, accounting for 6.90% of the total shares.
Morgan Stanley & Co. LLC holds 1.47M shares, accounting for 3.19% of the total shares.
Jefferies LLC holds 2.20M shares, accounting for 4.75% of the total shares.
What are the top three shareholder types of Urogen Pharma Ltd?
The top three shareholder types of Urogen Pharma Ltd are:
RTW Investments L.P.
Paradigm BioCapital Advisors LP
TD Securities, Inc.
RTW Investments L.P.
Paradigm BioCapital Advisors LP
TD Securities, Inc.
How many institutions hold shares of Urogen Pharma Ltd (URGN)?
As of 2025Q3, 311 institutions hold shares of Urogen Pharma Ltd, with a combined market value of approximately 45.66M, accounting for 97.55% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -17.17%.
What is the biggest source of revenue for Urogen Pharma Ltd?
In FY2025Q2, the Jelmyto business generated the highest revenue for Urogen Pharma Ltd, amounting to 24.21M and accounting for --% of total revenue.
